Literature DB >> 12131530

Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension.

Daniel T O'Connor1, Mala T Kailasam, Brian P Kennedy, Michael G Ziegler, Noboru Yanaihara, Robert J Parmer.   

Abstract

BACKGROUND: Hypertension is a complex trait with an ill-defined genetic predisposition, in which adrenergic mechanisms seem to be involved even at the early stages. Chromogranin A is a pro-hormone stored and released with catecholamines by exocytosis; its fragment catestatin, formed in vivo, inhibits further catecholamine release as an antagonist at the physiologic trigger for secretion, the neuronal nicotinic cholinergic receptor.
METHODS: We measured catestatin by radioimmunoassay in n = 277 subjects stratified by blood pressure (n = 61 hypertensive, n = 216 normotensive), and if normotensive by genetic risk of developing hypertension: family history positive (n = 176) versus negative (n = 40). Maximum likelihood analysis tested for bimodality. Involvement of catestatin in pathophysiology was probed by measurements of catecholamines and leptin, and the hemodynamic responses to environmental (cold) stress.
RESULTS: The normotensive offspring of patients with hypertension already had diminished catestatin (P = 0.024), and family history was a better predictor of catestatin than age, ethnicity or gender (P = 0.014). Greater catestatin variance among family history-positive individuals (P = 0.021) suggested heterogeneity in this group, and a bimodal distribution (P < 0.001) identified 4.3% of individuals in a lower mode of catestatin values, all with positive family histories (P = 0.05). Catestatin correlated inversely with body mass index (r = -0.215, r(2) = 0.046, n = 276, P < 0.001) and plasma leptin (r = -0.203, r(2) = 0.041, n = 212, P = 0.003), while body mass index and leptin correlated directly (r = 0.59, r(2) = 0.350, n = 212, P < 0.001). Family history-positive individuals had greater epinephrine excretion (P = 0.037) in addition to diminished catestatin, suggesting an inhibitory effect of catestatin on chromaffin cells in vivo. Low plasma catestatin predicted enhanced pressor response to a sympathoadrenal stressor (cold stress; r = -0.184, r(2) = 0.034, n = 211, P = 0.007), suggesting an adrenergic mechanism whereby diminished catestatin might predispose to later development of hypertension. In white subjects, diminished catestatin also predicted greater systemic vascular resistance responses to cold stress (r = -0.307, r(2) = 0.094, n = 75, P = 0.007), a relationship not found in Blacks (r = 0.122, r(2) = 0.015, n = 94, P = 0.243).
CONCLUSIONS: We conclude that catestatin is diminished early in the course of development of hypertension, even in the normotensive offspring of patients with the disease. Low catestatin predicts augmented adrenergic pressor responses, suggesting a mechanism whereby diminished catestatin might increase the risk for later development of hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12131530     DOI: 10.1097/00004872-200207000-00020

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  81 in total

1.  Molecular Mechanism for Hypertensive Renal Disease: Differential Regulation of Chromogranin A Expression at 3'-Untranslated Region Polymorphism C+87T by MicroRNA-107.

Authors:  Kuixing Zhang; Saiful A Mir; C Makena Hightower; Jose Pablo Miramontes-Gonzalez; Adam X Maihofer; Yuqing Chen; Sushil K Mahata; Caroline M Nievergelt; Nicholas J Schork; Barry I Freedman; Sucheta M Vaingankar; Daniel T O'Connor
Journal:  J Am Soc Nephrol       Date:  2014-11-12       Impact factor: 10.121

Review 2.  Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-01-28

3.  Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin a (Chga) gene.

Authors:  Jiaur R Gayen; Kuixing Zhang; Satish P RamachandraRao; Manjula Mahata; Yuqing Chen; Hyung-Suk Kim; Robert K Naviaux; Kumar Sharma; Sushil K Mahata; Daniel T O'Connor
Journal:  Circ Cardiovasc Genet       Date:  2010-08-20

4.  Leukocyte telomere length and plasma catestatin and myeloid-related protein 8/14 concentrations in children with obstructive sleep apnea.

Authors:  Jinkwan Kim; Seungkwan Lee; Rakesh Bhattacharjee; Abdelnaby Khalyfa; Leila Kheirandish-Gozal; David Gozal
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

5.  Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk.

Authors:  Lian Zhang; Fangwen Rao; Kuixing Zhang; Srikrishna Khandrika; Madhusudan Das; Sucheta M Vaingankar; Xuping Bao; Brinda K Rana; Douglas W Smith; Jennifer Wessel; Rany M Salem; Juan L Rodriguez-Flores; Sushil K Mahata; Nicholas J Schork; Michael G Ziegler; Daniel T O'Connor
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

6.  Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin.

Authors:  Nilima Biswas; Sucheta M Vaingankar; Manjula Mahata; Madhusudan Das; Jiaur R Gayen; Laurent Taupenot; Justin W Torpey; Daniel T O'Connor; Sushil K Mahata
Journal:  Endocrinology       Date:  2007-11-08       Impact factor: 4.736

7.  Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic "rescue" of disease phenotypes in the mouse Chga knockout.

Authors:  Sucheta M Vaingankar; Ying Li; Angelo Corti; Nilima Biswas; Jiaur Gayen; Daniel T O'Connor; Sushil K Mahata
Journal:  Physiol Genomics       Date:  2009-12-15       Impact factor: 3.107

8.  Human dopamine beta-hydroxylase (DBH) regulatory polymorphism that influences enzymatic activity, autonomic function, and blood pressure.

Authors:  Yuqing Chen; Gen Wen; Fangwen Rao; Kuixing Zhang; Lei Wang; Juan L Rodriguez-Flores; Amber P Sanchez; Manjula Mahata; Laurent Taupenot; Ping Sun; Sushil K Mahata; Bamidele Tayo; Nicholas J Schork; Michael G Ziegler; Bruce A Hamilton; Daniel T O'Connor
Journal:  J Hypertens       Date:  2010-01       Impact factor: 4.844

9.  Autonomic function in hypertension; role of genetic variation at the catecholamine storage vesicle protein chromogranin B.

Authors:  Kuixing Zhang; Fangwen Rao; Brinda K Rana; Jiaur R Gayen; Federico Calegari; Angus King; Patrizia Rosa; Wieland B Huttner; Mats Stridsberg; Manjula Mahata; Sucheta Vaingankar; Vafa Mahboubi; Rany M Salem; Juan L Rodriguez-Flores; Maple M Fung; Douglas W Smith; Nicholas J Schork; Michael G Ziegler; Laurent Taupenot; Sushil K Mahata; Daniel T O'Connor
Journal:  Circ Cardiovasc Genet       Date:  2009-02

10.  Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification.

Authors:  Ryan S Friese; Jiaur R Gayen; Nitish R Mahapatra; Geert W Schmid-Schönbein; Daniel T O'Connor; Sushil K Mahata
Journal:  Physiol Genomics       Date:  2009-12-01       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.